# US 2024/0197659 A1 · Methods for treating symptoms of kabuki syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197659 A1
- Document ID: US20240197659A1
- Status: Published application
- Kind: A1
- Application number: 18/556,969
- Filed: 2022-04-26
- Published: 2024-06-20
- Earliest claimed: 2021-04-26
- Assignees: University of South Florida
- Applicants: University of South Florida
- Inventors: Dominic D'AGOSTINO; Sara E. MOSS; Angela Marie POFF
- Web page: https://patentgrep.com/patent/US20240197659A1

## CPC

- A23L 33/12: Fatty acids or derivatives thereof
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides methods of treating medical disorders, and more particularly methods for treating one or more symptoms of Kabuki Syndrome.

## Claims

### Claim 1

A method of treating, attenuating, mitigating, or ameliorating one or more symptoms of Kabuki Syndrome in a subject in need thereof, the method comprising administering a therapeutically effective amount of a ketogenic composition comprising a ketogenic compound.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the Kabuki Syndrome is Type 1 Kabuki Syndrome.

### Claim 5 (depends on 1)

The method of claim 1, wherein the Kabuki Syndrome is Type 2 Kabuki Syndrome.

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more symptoms are selected from long eyelashes, depressed nasal tip, atypical fingerprints, ear deformity, hypotonia, joint hyper-flexibility, ptosis, blue sclera, café au lait spot, genitourinary abnormalities, gastrointestinal abnormalities, hearing loss, immune deficiencies, feeding difficulties, obesity, short stature, poor sleep, hyperinsulinemia, hypoglycemia, epilepsy, cardiac defects, vertebral anomalies, sparse lateral eyelash, finger anomalies, cleft palate, dental issues, precocious puberty, scoliosis, and hip dysplasia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ketogenic compound comprises a ketone ester, a ketone salt, a ketone body precursor, or a combination thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the ketogenic compound comprises a beta-hydroxybutyrate (BHB).

### Claim 9 (depends on 1)

The method of claim 1, wherein the ketogenic composition further comprises a medium chain triglyceride (MCT).

### Claim 10 (depends on 9)

The method of claim 9, wherein the ketogenic compound and the MCT are present at about a 1:1 ratio.

### Claim 11 (depends on 9)

The method of claim 9, wherein the ketogenic compound and the MCT are present in an amount from about 5% to about 25% by weight of the composition.

### Claim 12 (depends on 9)

The method of claim 9, wherein the ketogenic compound and the MCT are present in an amount of about 15% by weight of the composition.

### Claim 13

A method of treating one or more symptoms of Kabuki Syndrome in a subject in need thereof comprising administering a therapeutically effective amount of a ketogenic composition to the subject,
wherein the ketogenic composition comprises a beta-hydroxybutyrate (BHB) and a medium chain triglyceride (MCT).

### Claim 14 (depends on 13)

The method of claim 13, wherein the BHB and the MCT are present at about a 1:1 ratio.

### Claim 15 (depends on 13)

The method of claim 13, wherein treating one or more symptoms of Kabuki Syndrome comprises attenuating, mitigating, or ameliorating the one or more symptoms of Kabuki Syndrome.

### Claim 16 (depends on 13)

The method of claim 13, wherein the subject is a human.

### Claim 17 (depends on 13)

The method of claim 13, wherein the Kabuki Syndrome is Type 1 Kabuki Syndrome.

### Claim 18 (depends on 13)

The method of claim 13, wherein the Kabuki Syndrome is Type 2 Kabuki Syndrome.

### Claim 19 (depends on 13)

The method of claim 13, wherein the one or more symptoms are selected from long eyelashes, depressed nasal tip, atypical fingerprints, ear deformity, hypotonia, joint hyper-flexibility, ptosis, blue sclera, café au lait spot, genitourinary abnormalities, gastrointestinal abnormalities, hearing loss, immune deficiencies, feeding difficulties, obesity, short stature, poor sleep, hyperinsulinemia, hypoglycemia, epilepsy, cardiac defects, vertebral anomalies, sparse lateral eyelash, finger anomalies, cleft palate, dental issues, precocious puberty, scoliosis, and hip dysplasia.

### Claim 20 (depends on 13)

The method of claim 13, wherein the BHB and the MCT are present in an amount from about 5% to about 25% by weight of the composition

### Claim 21 (depends on 13)

The method of claim 13, wherein the BHB and MCT are present in an amount of about 15% by weight of the composition.

### Claim at position 22

22-37. (canceled)
